^
Association details:
Biomarker:No biomarker
Cancer:Bladder Cancer
Drug:belzupacap sarotalocan (AU-011) (Reactive oxygen species stimulant)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Published date:
06/30/2022
Excerpt:
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).